Wedbush Reiterates Outperform on Alpine Immune Sciences, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated his 'Outperform' rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a price target of $19.
September 01, 2023 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alpine Immune Sciences (NASDAQ:ALPN) has had its 'Outperform' rating reiterated and its price target maintained at $19 by Wedbush analyst Robert Driscoll.
The reiteration of the 'Outperform' rating and the maintenance of the $19 price target by Wedbush analyst Robert Driscoll indicates a positive outlook for Alpine Immune Sciences. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100